Impact of breast cancer on anti-mullerian hormone levels in young women

H. Irene Su(University of California San Diego), Anne Z. Steiner(Children's Hospital of Los Angeles), Angela DeMichele(University of Pennsylvania), Loki Natarajan(General Department of Preventive Medicine), Shirley W. Flatt(University of California San Diego)
Breast Cancer Research and Treatment
December 8, 2012
10.1007/s10549-012-2361-5
Cited by 52

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
|Cell|2017|448
(untitled)
|Edinburgh Research Explorer|0|353